Metaraminol: Difference between revisions
m (Protected "Metaraminol": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 22: | Line 22: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 36: | Line 32: | ||
==References== | ==References== | ||
{{reflist|2}} | |||
{{Adrenergic and dopaminergic agents}} | {{Adrenergic and dopaminergic agents}} | ||
[[Category:Sympathomimetic amines]] | [[Category:Sympathomimetic amines]] | ||
[[Category:Drugs]] | [[Category:Amphetamines]] | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] | |||
Latest revision as of 00:03, 24 July 2014
 | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | ~45% |
| Metabolism | Hepatic |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C9H13NO2 |
| Molar mass | 167.205 g/mol |
|
WikiDoc Resources for Metaraminol |
|
Articles |
|---|
|
Most recent articles on Metaraminol Most cited articles on Metaraminol |
|
Media |
|
Powerpoint slides on Metaraminol |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Metaraminol at Clinical Trials.gov Clinical Trials on Metaraminol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Metaraminol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Metaraminol Discussion groups on Metaraminol Patient Handouts on Metaraminol Directions to Hospitals Treating Metaraminol Risk calculators and risk factors for Metaraminol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Metaraminol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Metaraminol (INN, trade name Aramine) is a potent sympathomimetic amine used in the prevention and treatment of hypotension, particularly as a complication of anesthesia. It is an α1-adrenergic receptor agonist with some β effect.
Metaraminol is also used in the treatment of priapism. Although not approved for this use, it appears to be effective.[1][2][3]
References
- ↑ McDonald M, Santucci R (2004). "Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol". Int Braz J Urol. 30 (2): 121–2. PMID 15703094.
- ↑ Koga S, Shiraishi K, Saito Y (1990). "Post-traumatic priapism treated with metaraminol bitartrate: case report". J Trauma. 30 (12): 1591–3. PMID 2258979.
- ↑ Block T, Sturm W, Ernst G, Staehler G, Schmiedt E (1988). "[Metaraminol in therapy of various forms of priapism]". Urologe A. 27 (4): 225–9. PMID 3140463.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Sympathomimetic amines
- Amphetamines
- Cardiovascular Drugs
- Drug